80 FR 232 pg. 75690 - Manufacturer of Controlled Substances Registration: Navinta, LLC
Type: NOTICEVolume: 80Number: 232Page: 75690
Page: 75690Docket number: [Docket No. DEA-392]
FR document: [FR Doc. 2015-30558 Filed 12-2-15; 8:45 am]
Agency: Justice Department
Sub Agency: Drug Enforcement Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Manufacturer of Controlled Substances Registration: Navinta, LLC
ACTION:
Notice of registration.
SUMMARY:
Navinta, LLC applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Navinta, LLC registration as a manufacturer of those controlled substances.
SUPPLEMENTARY INFORMATION:
By notice dated June 25, 2015, and published in the Federal Register on July 6, 2015, 80 FR 38471, Navinta, LLC, 1499 Lower Ferry Road, Ewing, New Jersey 08618-1414 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted for this notice.
The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Navinta, LLC to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the following basic classes of controlled substances:
| Controlled substance | Schedule |
|---|---|
| 4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333) | II |
| Fentanyl (9801) | II |
The company plans initially to manufacture API quantities of the listed controlled substances for validation purposes and FDA approval, then eventually upon FDA approval to produce commercial size batches for distribution to dosage form manufacturers.
Dated: November 23, 2015.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2015-30558 Filed 12-2-15; 8:45 am]
BILLING CODE 4410-09-P